Group A streptococci are one of the most common pathogens that humans are exposed to, and they can cause infections with a wide range of severities, from mild rashes and sore throats to flesh-eating and systemic infections that can be fatal. The number of these infections is also on the rise, although the reasons are unclear. Now researchers have learned more about why these pathogens can be mild in some people, and hit others hard. The findings have been reported in Nature Communications.
Scientists suspected that some interaction between a person’s genetics and the bacterial pathogen could be leading to such varied outcomes, said study co-author Fredric Carlsson, a researcher at Lund University.
A genetically modified pig kidney transplanted into a brain-dead man on life support has exhibited regular functioning for over a month, showing no signs of rejection or infection.
A new milestone in animal-to-human organ transplants in the United States has been achieved.
A gene-edited pig kidney implanted into a brain-dead man on life support has been functioning normally for over a month with no signs of rejection or infection.
Researchers from Monash University in Melbourne and The University of Western Australia have demonstrated how a reprogramming method imitates embryonic epigenetic reset. Transient naive treatment (TNT) reprogrammed human induced pluripotent stem (hiPS) cells that are molecularly and functionally more similar to human embryonic stem (hES) cells than primed hiPS cells, which are more like cells in the post-implantation embryo. This research suggests that TNT reprogramming has the potential to set a new standard for therapeutic and biomedical uses.
“Our work shows that TNT reprogramming is a practical and scalable approach to overcome these intrinsic characteristics of hiPS cells, which is important for the clinical delivery of this technology,” stated the authors. “We foresee TNT reprogramming becoming a new standard for biomedical and therapeutic applications.”
Since 2014, the ALS Ice Bucket Challenge has inspired more than 17 million people to raise $115 million for The ALS Association, which has funded over 500 research projects with the money. Because of that boost, the first drug to treat ALS has been approved by the FDA, other new treatments are in testing, and scientists have been able to identify several genes that are connected to the disease.
While mutations in a gene called NEK1 have only been associated with around two percent of ALS cases, it is one of the primary genetic causes of ALS that have been revealed so far. Now investigators have learned more about how NEK1 mutations can lead to ALS, a disease in which the motor neurons that control movement degenerate and die, which causes paralysis and eventually, death. The work has been reported in Science Advances.
In a recent pre-print study posted to the medRxiv* server, researchers conducted a comprehensive genome-wide association study (GWAS) to elucidate the genetic architecture of circulating retinol, identify its potential causal relationships with various clinical phenotypes, and evaluate its therapeutic or nutritional implications.
Study: Genetic influences on circulating retinol and its relationship to human health. Image Credit: SciePro/Shutterstock.com.
*Important notice: medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information.
Benjamin Oakes’ Scribe Therapeutics is developing specialized Crispr proteins to tackle a wide range of diseases–and it’s garnered deals with Big Pharma potentially worth over $4 billion.
Genome-wide association analyses of magnetic resonance imaging data describe the genetic architecture of 13 cortical phenotypes at both global and regional levels, implicating neurodevelopmental and constrained genes.
A new method allows large quantities of muscle stem cells to be safely obtained in cell culture. This provides a potential for treating patients with muscle diseases – and for those who would like to eat meat, but don’t want to kill animals.
Elon Musk delves into the groundbreaking potential of Neuralink, a revolutionary venture aimed at interfacing with the human brain to tackle an array of brain-related disorders. Musk envisions a future where Neuralink’s advancements lead to the resolution of conditions like autism, schizophrenia, memory loss, and even spinal cord injuries.
Elon Musk discusses the transformative power of Neuralink, highlighting its role in restoring motor control after spinal cord injuries, revitalizing brain function post-stroke, and combating genetically or trauma-induced brain diseases. Musk’s compelling insights reveal how interfacing with neurons at an intricate level can pave the way for repairing and enhancing brain circuits using cutting-edge technology.
Discover the three-layer framework Musk envisions: the primary layer akin to the limbic system, the more intelligent cortex as the secondary layer, and the potential tertiary layer where digital superintelligence might exist. Musk’s thought-provoking perspective raises optimism about the coexistence of a digital superintelligence with the human brain, fostering a harmonious relationship between these layers of consciousness.
Elon Musk emphasises the urgency of Neuralink’s mission, stressing the importance of developing a human brain interface before the advent of digital superintelligence and the elusive singularity. By doing so, he believes we can mitigate existential risks and ensure a stable future for humanity and consciousness as we navigate the uncharted territories of technological evolution.
A research team co-led by City University of Hong Kong (CityU) and The University of Hong Kong (HKU) has recently made a significant advancement in spinal cord injury treatment by using genetically-modified human neural stem cells (hNSCs).
They found that specifically modulating a gene expression to a certain level in hNSCs can effectively promote the reconstruction of damaged neural circuits and restore locomotor functions, offering great potential for new therapeutic opportunities for patients with spinal cord injury. The findings were published in the journal Advanced Science under the title “Transplanting Human Neural Stem Cells with ≈50% Reduction of SOX9 Gene Dosage Promotes Tissue Repair and Functional Recovery from Severe Spinal Cord Injury.”
Traumatic spinal cord injury is a devastating condition that commonly results from accidents such as falls, car crashes or sport-related injuries.
